Crizotinib is currently used to treat ALK-rearranged cancers, such as anaplastic large-cell lymphoma (ALCL) and non-small cell lung cancer (NSCLC), and crizotinib has demonstrated efficacy in treating ALK-positive IMT as well. The gene discussed is ALK; the disease is inflammatory myofibroblastic tumor.